Frankfurt - Delayed Quote • EUR
4SC AG (VSC.F)
At close: April 26 at 3:24 PM GMT+2
Key Executives
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Jason Loveridge B.Sc., FRSM, Ph.D. | Chairman of Management Board, CEO & MD | 519k | -- | -- |
| Ms. Kathleen Masch-Wiest | COO & Member of the Management Board | -- | -- | -- |
| Ms. Anna Niedl Ph.D. | Corporate Communications & Investor Relations Officer | -- | -- | -- |
| Dr. Susanne Danhauser-Riedl M.D. | Chief Medical Officer | -- | -- | -- |
| Ms. Larissa Stuttem | Team Assistant | -- | -- | -- |
4SC AG
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 13
Description
4SC AG, a biopharmaceutical company, engages in developing small-molecule drugs that address cancer diseases with high unmet medical needs in Germany. Its product Resminostat, an orally administered histone deacetylase inhibitor for the treatment of cutaneous T-cell lymphoma, which is in clinical development stage. The company also out-licenses its products to pharma and biotech companies. The company was founded in 1997 and is headquartered in Planegg, Germany.
Corporate Governance
4SC AG’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Recent Events
Recent Events Information Not Available
Upcoming Events
Apr 18, 2024
4SC AG Earnings Call
Related Tickers
MDG1.F Medigene AG
1.5250
+1.67%
HPHA.F Heidelberg Pharma AG
2.9100
-1.02%
05Y.F Vivoryon Therapeutics N.V.
0.7840
-6.33%
MDG1.DE Medigene AG
1.5050
-5.64%
CLABF Core One Labs Inc.
0.1435
-5.20%
SCNI Scinai Immunotherapeutics Ltd.
0.4578
+1.73%
BSLN.SW Basilea Pharmaceutica AG
40.30
+0.12%
CTNM Contineum Therapeutics, Inc.
15.72
-1.69%
FENC Fennec Pharmaceuticals Inc.
9.21
+0.55%
GYRE Gyre Therapeutics, Inc.
17.11
+4.78%